Osteoporosis is a global problem that ...

(Reuters) - Amgen Inc drug to treat osteoporosis in women increased bone mineral density (IPC), an important determinant of bone strength, biotechnology company. The study Phase 2 expansion showed that for postmenopausal women with low bone mass or osteoporosis who received up to eight years of continuous treatment with Prolia (denosumab), bone mineral density increased by an average of 16. 8 percent in the lumbar spine lasix online and 6. 9 percent of the total hip, Amgen said. Prolia is the first approved therapy that specifically targets an essential regulator of osteoclasts, cells that destroy cells that destroy bone. Osteoporosis is a global problem that is growing in importance as the world's population ages. World Health Organization declared the osteoporosis crisis in health care. (Reporting Nick Zieminski, editing Maureen Bavdek).